SPOTLIGHT -
COVID-19’s Effect on Clinical Trials of Long-Acting Cabotegravir and Rilpivirine for HIV Infection
How has the COVID-19 pandemic affected clinical trial site restrictions, drug delivery, dosing, patient monitoring, and follow-up?
Read More
DAV132, Novel Colon-Targeted Adsorbent, Protects Intestinal Microbiota From Antibiotic-Induced Dysbiosis
The composition of the gut microbiome is easily disrupted by antibiotics, leaving the host susceptible to further infection or other disturbance of gut flora that can lead to both short- and long-term deleterious effects.
How the COVID-19 Pandemic Has Affected Physician Economic Burden and Workload
In results of a national survey, investigators pieced together a look at the psychological toll of the pandemic on physicians and identified the biggest stressors.
CovidIQ Text Tool Successfully Predicts COVID-19 Hot Spots Before Agencies
The CovidIQ tool successfully predicted a COVID-19 spike in Jacksonville, Florida, a full 2 weeks before it was recognized by the Florida Department of Health.
ALLIUM Trial: Cefepime-Enmetazobactam Superior to Piperacillin-Tazobactam for ESBL-Producing Enterobacterales
Antimicrobial-resistant infections, in particular those caused by gram-negative pathogens that also produce extended spectrum β-lactamases (ESBL), represent a growing threat across the globe as investigators race to develop novel therapeutics
ERADICATE Hp2: RHB-105 Could Fill Treatment Gap for H Pylori
RHB-105 is an “all-in-one” fixed-dose oral capsule comprising rifabutin 50 mg, amoxicillin 1000 mg, and omeprazole 40 mg.
